

Daniel S Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/40909/publications.pdf>

Version: 2024-02-01

56
papers

33,075
citations

109137

35
h-index

205818

48
g-index

57
all docs

57
docs citations

57
times ranked

36422
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, . | 5.8 | 229 |
| 2 | Top 10 Challenges in Cancer Immunotherapy. <i>Immunity</i> , 2020, 52, 17-35. | 6.6 | 1,177 |
| 3 | Insights from immuno-oncology; the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878. | | 63 |
| 4 | Abstract 5664: A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine release. , 2020, , . | | 3 |
| 5 | Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. <i>Clinical Cancer Research</i> , 2019, 25, 6061-6072. | 3.2 | 58 |
| 6 | VEGF in Signaling and Disease: Beyond Discovery and Development. <i>Cell</i> , 2019, 176, 1248-1264. | 13.5 | 1,468 |
| 7 | TGF β 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548. | 13.7 | 3,359 |
| 8 | Introduction by the Guest Editors. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 163-164. | 1.0 | 0 |
| 9 | Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 850-858. | 0.8 | 288 |
| 10 | Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti- α PD-L1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10119-E10126. | 3.3 | 180 |
| 11 | Combinations of Bevacizumab With Cancer Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 193-204. | 1.0 | 144 |
| 12 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757. | 15.2 | 900 |
| 13 | Abstract 2979: A balance of genomic instability, tumor-immune contexture and TGF- β 2 signaling contributing to exclusion of T cells governs response to PD-L1 checkpoint blockade. , 2018, , . | | 1 |
| 14 | Elements of cancer immunity and the cancer- α immune set point. <i>Nature</i> , 2017, 541, 321-330. | 13.7 | 3,558 |
| 15 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet, The</i> , 2017, 389, 255-265. | 6.3 | 3,872 |
| 16 | New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31st Annual Meeting of the Society for Immunotherapy of Cancer, 2016. , 2017, 5, 50. | | 10 |
| 17 | Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitinib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients. <i>Cancer Research</i> , 2017, 77, CT081-CT081. | 0.4 | 9 |
| 18 | De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. <i>Cancer Immunology Research</i> , 2016, 4, 279-288. | 1.6 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). <i>Annals of Oncology</i> , 2016, 27, 1492-1504. | 0.6 | 460 |
| 20 | Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. <i>Nature Communications</i> , 2016, 7, 12624. | 5.8 | 550 |
| 21 | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1837-1846. | 6.3 | 2,390 |
| 22 | Association of PD-L2 expression in human tumors with atezolizumab activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11506-11506. | 0.8 | 22 |
| 23 | Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9028-9028. | 0.8 | 16 |
| 24 | Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9032-9032. | 0.8 | 14 |
| 25 | Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). <i>Cancer Research</i> , 2015, 75, 2859-2859. | 0.4 | 128 |
| 26 | Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. <i>Cancer Research</i> , 2015, 75, PD1-6-PD1-6. | 0.4 | 25 |
| 27 | Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3015-3015. | 0.8 | 9 |
| 28 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>Nature</i> , 2014, 515, 558-562. | 13.7 | 2,109 |
| 29 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014, 515, 563-567. | 13.7 | 4,342 |
| 30 | Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5011-5011. | 0.8 | 49 |
| 31 | Oncology Meets Immunology: The Cancer-Immunity Cycle. <i>Immunity</i> , 2013, 39, 1-10. | 6.6 | 4,815 |
| 32 | Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab. <i>Clinical Cancer Research</i> , 2013, 19, 929-937. | 3.2 | 179 |
| 33 | Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies. <i>Clinical Cancer Research</i> , 2013, 19, 3681-3692. | 3.2 | 53 |
| 34 | Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. <i>Journal of Clinical Investigation</i> , 2013, 123, 3997-4009. | 3.9 | 33 |
| 35 | Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. , 2013, , . | | 15 |
| 36 | A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3000-3000. | 0.8 | 116 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.. Journal of Clinical Oncology, 2013, 31, 3001-3001. | 0.8 | 33 |
| 38 | Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.. Journal of Clinical Oncology, 2013, 31, 3622-3622. | 0.8 | 17 |
| 39 | Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8008-8008. | 0.8 | 44 |
| 40 | Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).. Journal of Clinical Oncology, 2013, 31, 9010-9010. | 0.8 | 118 |
| 41 | Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 2012, 366, 2035-2036. | 13.9 | 122 |
| 42 | BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of Clinical Oncology, 2012, 30, 34-41. | 0.8 | 172 |
| 43 | Molecular Pathways: Next-Generation Immunotherapyâ€”Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clinical Cancer Research, 2012, 18, 6580-6587. | 3.2 | 543 |
| 44 | A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. Translational Oncology, 2012, 5, 404-407. | 1.7 | 220 |
| 45 | Anti-Angiogenesis Therapy in Melanoma. , 2012, , 155-184. | | 0 |
| 46 | Abstract 1385: Molecular changes in breast tumors following bevacizumab-based treatment: Final analysis of a randomized neoadjuvant study of bevacizumab or placebo, followed by chemotherapy with or without bevacizumab, in patients with stage II or III breast cancer. , 2012, , . | | 0 |
| 47 | Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 372-381. | 3.2 | 89 |
| 48 | Abstract 5130: Neuropilin-1 expression in breast, colorectal and lung cancer. , 2011, , . | | 0 |
| 49 | Molecular Biomarker Analyses Using Circulating Tumor Cells. PLoS ONE, 2010, 5, e12517. | 1.1 | 271 |
| 50 | T cells use two directionally distinct pathways for cytokine secretion. Nature Immunology, 2006, 7, 247-255. | 7.0 | 396 |
| 51 | Cellular immunotherapy: antigen recognition is just the beginning. Seminars in Immunopathology, 2005, 27, 119-127. | 4.0 | 11 |
| 52 | Marked Differences in Human Melanoma Antigen-Specific T Cell Responsiveness after Vaccination Using a Functional Microarray. PLoS Medicine, 2005, 2, e265. | 3.9 | 77 |
| 53 | Detection and Characterization of Cellular Immune Responses Using Peptideâ€”MHC Microarrays. PLoS Biology, 2003, 1, e65. | 2.6 | 131 |
| 54 | Retroviral Vector-Mediated Transfer of an Antisense Cyclin G1 Construct Inhibits Osteosarcoma Tumor Growth in Nude Mice. Human Gene Therapy, 1997, 8, 1667-1674. | 1.4 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Mouse Hepatitis Virus Infection Induces an Early, Transient Calcium Influx in Mouse Astrocytoma Cells. <i>Experimental Cell Research</i> , 1997, 237, 55-62. | 1.2 | 12 |
| 56 | A pregnancy-specific glycoprotein is expressed in the brain and serves as a receptor for mouse hepatitis virus.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 12095-12099. | 3.3 | 85 |